Bausch Health Companies (NYSE:BHC) has received FDA approval for its triple-combination topical medication Cabtreo for the treatment of acne vulgaris.
The product, which is approved for acne patients aged 12 or older, is a combination of clindamycin phosphate, adapalene and benzoyl peroxide. Bausch expects to launch the product in Q1 2024.
Bausch said the product helps acne patients by combining three acne treatments into a once-daily topical treatment.
Last month, SA analyst Edgar Torres H rated Bausch a sell, commenting that the company “faces financial and strategic challenges, with declining revenues and a concentrated portfolio.”
Bausch Health gets FDA approval for acne treatment Cabtreo
